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Abstract
We present the results of a global study of dysregulated miRNAs in paired samples of normal mucosa and tumor from
eight patients with colorectal cancer. Although there is existing data of miRNA contribution to colorectal tumorigenesis,
these studies are typically small to medium scale studies of cell lines or non-paired tumor samples. The present study is
to our knowledge unique in two respects. Firstly, the normal and adjacent tumor tissue samples are paired, thus taking
into account the baseline differences between individuals when testing for differential expression. Secondly, we use
high-throughput sequencing, thus enabling a comprehensive survey of all miRNAs expressed in the tissues. We use
Illumina sequencing technology to perform sequencing and two different tools to statistically test for differences in
read counts per gene between samples: edgeR when using the pair information and DESeq when ignoring this
information, i.e., treating tumor and normal samples as independent groups. We identify 37 miRNAs that are
significantly dysregulated in both statistical approaches, 19 down-regulated and 18 up-regulated. Some of these
miRNAs are previously published as potential regulators in colorectal adenocarcinomas such as miR-1, miR-96 and miR-
145. Our comprehensive survey of differentially expressed miRNAs thus confirms some existing findings. We have also
discovered 16 dysregulated miRNAs, which to our knowledge have not previously been associated with colorectal
carcinogenesis: the following significantly down-regulated miR-490-3p, -628-3p/-5p, -1297, -3151, -3163, -3622a-5p, -
3656 and the up-regulated miR-105, -549, -1269, -1827, -3144-3p, -3177, -3180-3p, -4326. Although the study is
preliminary with only eight patients included, we believe the results add to the present knowledge on miRNA
dysregulation in colorectal carcinogenesis. As such the results would serve as a robust training set for validation of
potential biomarkers in a larger cohort study. Finally, we also present data supporting the hypothesis that there are
differences in miRNA expression between adenocarcinomas and neuroendocrine tumors of the colon.
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Introduction
Colorectal cancer (CRC) is one of the most frequently occurring
cancers worldwide [1]. Prognosis depends on tumor stage at the
time of diagnosis. There is high focus on discovery and validation
of early detection markers as well as on predictive and prognostic
factors as reviewed by Asghar et al. [2]. The molecular genesis of
CRC is among the best described of all human cancers. The
Vogelstein model [3] has over the years been modified and
extended, as exemplified by Slaby et al. [4].
MicroRNAs (miRs) are small non-coding RNA molecules 18-25
nucleotides in length, first discovered in the early 1990s in C. elegans
[5]. They maintain homeostasis by altering gene expression in
different cell processes such as differentiation, proliferation,
survival and apoptosis [6]. It is estimated that more than 10% of
all protein-encoding human genes may be regulated by these
mechanisms [7]. The latest number of human miRs recorded in
miRBase exceeds a thousand [8], and the increasing use of high-
throughput sequencing is driving further discovery. Studies have
also shown that miRs may be dysregulated in different human
cancers, and hence act as tumor suppressors or oncogenes [9,10].
These molecules are interesting since they may be potential
biomarkers of diagnosis or prognosis and act as potential targets in
cancer specific therapy as reviewed by Cho et al. [11,12]. The
ultimate goal would be personalized medicine with genotype-
phenotype cancer networks as the roadmap to clinical decisions
[13].
Many studies have focused on miR expression profiling in
colorectal cancer. Most of these studies have analyzed a smaller
number of miRs using real-time polymerase chain reaction (PCR)
or hybridization based technology, partly from cell lines or non-
paired patient tissues [14,15,16,17,18]. Only a few studies have
more globally sequenced miRs in a larger scale for the expression
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microRNAome. The latter study was unique in its kind and
presented a set of novel putative miRs by using an experimental
approach named miRAGE. However, as this study dates back
several years, only a subset of mature miRs known today was
actively investigated.
Global expression of miRs has traditionally been assessed using
hybridization based array technologies. These arrays are based on
sequence specific hybridization after labeling with a fluorescent
dye. Fluorescence intensity is recorded and reflects the expression
of a given gene. By using multiple dyes, the difference in
fluorescence may be used as an index of gene expression. High-
throughput sequencing, on the other hand, uses sample transcripts
as starting template. Direct sequencing is then performed with
a series of reactions using fluorophore terminator nucleotides.
Sequence reads are then mapped back to the reference genome or
a database of transcripts and the number of sequence reads
mapping back to a specific transcript is a measure of gene
expression. In the general case of mRNA, this count needs to be
normalized for the length of the transcript and the total number of
reads generated for the sample. In the case of miR, the
normalization for the transcript length is not required as the
reads cover the full-length of the transcript. Differential expression
is then measured by the difference in normalized counts for a given
gene. A recent publication compares differential gene expression
in D. pseudoobscura when using array technology and high-
throughput sequencing. The majority of expression levels are
similar between the methods with a comparable performance [21].
A similar study on S. cerevisiae has shown that the methods agree
fairly well for genes with medium levels of expression, but
correlation is very low for genes with either low or high expression
levels. This is partly due to the greatly increased dynamic range for
quantification of gene expression provided by the high-throughput
sequencing method [22]. High-throughput sequencing is further
considered superior when dealing with the structure and dynamics
of the transcriptome. Examples of this include expression of
unknown target sequences, RNA editing events and other RNA
sequence variations such as polymorphisms [21,22,23].
Since these features of high-throughput sequencing suggest that
it is an excellent method for global surveys of small RNAs, we
included eight patients with colorectal cancer undergoing surgical
resection of the colon for studying tumor specific changes in miR
expression using Illumina high-throughput sequencing technology.
Tissues of normal mucosa and tumor were collected from surgical
specimens for all patients, hence yielding a unique set of paired
samples. Our analysis of the sequence datasets we produced from
these samples enables us to identify miRs that have not previously
been associated with colorectal adenocarcinomas. We have also
identified differences in miR expression between adenocarcinomas
and a neuroendocrine tumor of the colon. These results add to the
present knowledge on miR dysregulation in colorectal carcino-
genesis.
Results
Eight patients were randomly selected according to gender
specifications (males only) from a colorectal cancer cohort. Total
RNA from tumor tissue and adjacent normal mucosa was
extracted. In preliminary analysis of differential expression
between tumor and adjacent normal mucosa, one pair demon-
strated an expression pattern different from the rest of the pairs.
Histopathology was reviewed by a pathologist (Table 1), and it was
evident that one patient was misclassified and harbored an atypical
neuroendocrine tumor (NET) whereas the rest were adenocarci-
nomas. All further statistical analyses treated the patient with NET
as one separate case from the remaining patients. The percentages
of tumor cells and stromal components were also estimated in
hematoxylin and eosin stained sections from primary tumor,
showing that seven of eight samples harbored more than 60%
tumor cells (Table 1).
The 16 samples were successfully sequenced using Illumina
Genome Analyzer II (Illumina, CA, USA) and processed using
miRanalyzer [24] with an average of 562 mature miRs mapped to
miRBase per sequencing experiment when permitting one
mismatch nucleotide (Figure 1B). Approximately 80% of sequenc-
ing reads mapped to mature human miRs in miRBase (release 16)
in seventeen of eighteen sequencing runs, the remaining reads
mostly map to other parts of the transcriptome. In the last sample
(normal tissue N7) there was a much lower percentage of reads
that map to miRBase (37.2% of the total reads) (Figure 1A). This
may be due to technical issues during sample preparation.
Furthermore, a few hundred putative novel miR sequences and
gene loci in the reference genome (hsa hg18) were predicted from
the sequencing runs. These putative sequences amount to a small
fraction of the total read count (data not shown).
Differential expression (DE) of identified miRs from miRBase
was calculated using two bioinformatic tools, DESeq [25] and
edgeR [26]. EdgeR implements functionality to perform both
paired and non-paired tests (the pair information is ignored, and
normal and tumor samples are treated as independent groups),
whereas DESeq cannot perform paired tests, but benefits from
additional statistical refinements relative to edgeR. Treating the
normal and tumor samples as two independent groups is
theoretically predicted to be the more conservative test since,
unlike the paired test, it does not account for baseline differences
between patients. By using both methods, we get two sets of
significantly differentially expressed miRs. The intersection be-
tween these two sets is a very conservative prediction of the
significantly dysregulated miRs. In addition, we were able to
observe to what extent the non-paired testing is more conservative
than the paired. First fold change of known miRs was analyzed
between the groups of adenocarcinoma (n=7) and normal mucosa
(n=8), subsequently between the neuroendocrine case (n=1) and
normal mucosa (n=8) using DESeq (Figures 2A and 2C). When
looking at the adenocarcinomas asa group and using the Benjamini
and Hochberg adjustment [27] for multiple testing (FDR , 0.1),
a total of 52 miRs were significantly dysregulated compared to that
of the normal mucosa: 28 were down-regulated and 24 up-
regulated (Table S1). The neuroendocrine case, however, demon-
strated a total of 38 miRs significantly dysregulated compared to
the normal mucosa group, all up-regulated (Table S2). Interest-
ingly, only 6 miRs are represented in both histopathological
groups: miR-7, -96, -204, -1269, -1827 and -3177. In this analysis
there are hence a total of 46 and 32 miRs that seem somewhat
specific to the adenocarcinoma and neuroendocrine histopathol-
ogy, respectively.
Since we were examining paired samples of tumor and normal
mucosal tissue from the same patients, we also performed a test of
the seven adenocarcinoma cases using paired statistics in edgeR
(Figure 2B). A total of 118 miRs were identified as significantly
dysregulated under the same conditions as for the non-paired
analysis (Table S3). Of these, there were 81 miRs that were not
identified in the non-paired analysis, and a common overlap of 37
for both approaches. This confirms the prediction that the non-
paired analysis is the more conservative test, although there are
15 miRs identified as dysregulated in the DESeq non-paired test
which were not identified by the paired analysis in edgeR
(Figure 3).
DE of miRNAs in CRC Using HTS
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34150It is apparent that there are 37 common miRs found to be
significantly dysregulated when using both statistical approaches
(Table 2). There is approximately equal distribution between the
down-andup-regulatedmiRs.Therearebothlowly(approximately
10–10 000 absolute reads) and highly (approximately 10 000–5 000
000absolutereads)expressedmiRsrepresentedinthecommonmiR
subset, two notable examples being miR-7 and miR-1, respectively.
When looking at expression levels globally in terms of all identified
miRs, there is a global up-regulation of expression in the tumor
compared to that of normal mucosa (considered from the paired
analysis ofthe adenocarcinomas).
The high-throughput sequencing was experimentally validated
using a quantitative polymerase chain reaction for selected miRs
and tissue specimens (Figure S1). Our results are in line with
previous inter-platform validation results [28]: the results between
the different methods correlate, but this correlation is far from
perfect.
Discussion
Several studies have found that miRs are globally down-
regulated in different cancers, with a correlation between the
degree of differentiation and global expression levels of miRs.
Although it has been indicated that global down-regulation
promotes cell transformation and tumorigenesis [10,15,29], a large
expression profiling study of solid tumors by Volinia et al. did not
observe down-regulation of miRs as previously reported [30]. Our
study suggests that global down-regulation is not the case for the
colorectal adenocarcinomas in our cohort, even though a sub-
stantial number of individual miRs are down-regulated in the
adenocarcinomas relative to the normal samples.
According to the miRecords database [31], miR-1 has 117
validated targets and could potentially interact with several
important genes in carcinogenesis of colorectal cancer. In a study
from 2009, miR-1 and miR-551b (among others) were found to
have lower expression in embryonic stem cells relative to
differentiated cells and in colorectal cancer relative to normal
mucosa [17]. This is consistent with our findings of down-
regulated miR-1 and miR-551b in the colorectal adenocarcino-
mas. Down-regulated miR-1 is also observed in the neuroendo-
crine case. miR-1 has further been reported to be down-regulated
and suggested a tumor-suppressive function by targeting the
transgelin 2 gene (TAGLN2) in bladder cancer [32] and head and
neck squamous cell carcinomas [33].
miR-145 is down-regulated in the adenocarcenomas of our
study, and this miR has frequently been associated with down-
regulation in colorectal cancers [16,34,35,36]. It is thought to have
a tumor-suppressor role, partly by targeting the insulin receptor
substrate 1 (ISR-1) and type I insulin-like growth factor receptor
(IGF-IR). Loss of miR-145 inhibition increases anti-apoptotic
signals in the cell and promote cell growth [37,38].
Table 1. Clinical and histopathological characteristics of patients in the study.
Patient ID Age Gender Histology Differentiation TNM classification Anatomic site
Est’d percentage
tumor/stoma
1 56 Male Neuroendocrine - T3 N3 Mx Coecum 85/15
2 71 Male Adenocarcinoma Moderate T3 N0 Mx Rectum 60/40
3 79 Male Adenocarcinoma Moderate T2 N0 Mx Coecum 80/20
4 62 Male Adenocarcinoma Moderate T3 N0 Mx Rectum 10/90
5 55 Male Adenocarcinoma Moderate T3 N0 Mx Sigmoid 65/35
6 49 Male Adenocarcinoma Moderate T3 N0 Mx Sigmoid 70/30
7 66 Male Adenocarcinoma Moderate T3 N2 Mx Rectum 75/25
8 44 Male Adenocarcinoma High T2 N0 Mx Rectum 90/10
doi:10.1371/journal.pone.0034150.t001
Figure 1. Read classification as predicted by miRanalyzer and miRBase. Panel A with percentage of sequencing reads mapped to mature
miRs (black) of the total reads per experiment. Panel B with number of mature miRs identified per sequencing experiment. The total number of
mature human miRs in miRBase release 16 (n=1212) is included as reference.
doi:10.1371/journal.pone.0034150.g001
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in 81 colorectal cancer tissues compared to matched normal
mucosa and this is in accordance with our results for the
adenocarcinomas. This miR is believed to target Bcl-2 and hence
exert its pro-apoptotic function when physiologically regulated
[39]. Another study showed that reduced expression of miR-195
occurred more often in patients with lymph node metastasis and
advanced tumor stage. Low expression levels were also poor
predictors of overall survival [40].
In two minor studies, one of colon cancer without lymph node
metastasis [41] and the other of gastric cancer [31], miR-378 was
found to be down-regulated in the tumors compared to normal
adjacent tissue as seen in our study. It has however been reported
that miR-378 promotes cell survival and tumor growth by
targeting Sufu and Fus-1 [42] and it may also play a modifying
role with other miRs in angiogenesis [43]. There is further
evidence that the Myc/miR-378/TOB2/cyclin D1 functional
module regulates oncogenic transformation [44].
miR-383 is also down-regulated in the adenocarcinomas
compared to normal tissue. To our knowledge this has not been
reported for colorectal adenocarcinomas, but has been observed in
a small study on gastric cancer [45]. There is good concordance
between our findings of down-regulated miRs in colorectal
adenocarcinomas and previously published reports. As well as
the miRs described above, we identified a significant number of
other uniformly down-regulated miRs, less referred to in the
literature; -139-5p, -363, -422a, -486-5p, -490-3p, -628-3p, -628-
5p, -1297, -3151, -3163, -3622a-5p and -3656 (Table 2). This
highlights the potential of high throughput sequencing as a tool for
identifying miRs potentially related to carcinogenesis that could
have been missed using array based technology.
miR-7 has a functional role in the differentiation of epithelial
cells in the intestine, reviewed by Tazawa et al. [46]. It is thought to
regulate the expression of transmembrane glycoprotein CD98
which has an important role in cell adhesion through interaction
with integrin beta-1. Up-regulation of miR-7 suppresses CD98
expression in Caco2-BBE cells and hence modulates beta-1-
integrin-laminin-1 interactions. This may further affect prolifera-
tion and differentiation of enterocytes during migration across the
crypt-villus axis [47]. miR-7 has been reported to function as
a tumor-suppressor in schwannomas [48] but as an oncogene in
lung squamous cell carcinomas [49]. There is emerging evidence
that increased EGFR expression is associated with an increased
miR-7 level, at least in squamous cell carcinomas. The miR-7 in
turn targets Ets2 repressor factor (ERF), attenuates EGFR
expression and modulates cell growth [49]. It is therefore possible
that miR-7 may function in several feedback and feedforward
loops, both as tumor-suppressor and oncogene depending on
tumor type. Our findings strongly suggest that miR-7 is up-
regulated in both colorectal adenocarcinomas and in the
neuroendocrine case. Based on previous findings and published
validated targets for miR-7 such as EGFR, PAK1, RAF1, IRS1/2
and CD98 [31], it is fair to hypothesize that this miR may be
involved in regulating intracellular signaling, growth and differ-
entiation of colorectal cancers.
The expressions of miR-96, miR-135b and miR-493 were
increased in several studies on colorectal cancer, as well as in our
study [14,17,50]. miR-135 has been shown to directly target the 39
UTR of APC and induce the downstream Wnt pathway [51]. Our
results also show that miR-552 and -592 expressions were
increased in the adenocarcinomas compared to normal tissues.
Previously published data for these two miRs demonstrated an up-
regulation in colorectal cancers with proficient mismatch repair
status (MMR) but down-regulation in MMR deficient tumors
relative to normal colon tissue [17]. Yoon et al observed that miR-
296 interacted with the 39 UTR of the CDKN1A (p21/WAF1)
gene, and that this miR was frequently up-regulated during
immortalization of human cells [52]. Interestingly, we also observe
an up-regulation of miR-296-3p. This miR could as such
contribute to carcinogenesis by inhibiting the p53-p21/WAF1
pathway.
There are not many publications on the function of miR-549
(Chr15 in KIAA1199), and to our knowledge none in relation to
colorectal cancer. Interestingly, the gene transcribing this miR is
localized in the KIAA1199 gene. This gene of uncertain function
has previously been reported to be strongly up-regulated in
colorectal adenomas (n=32) and carcinomas (n=25) analyzed in
Figure 2. Schematic illustration of statistical approach. Panels A
and C show approach using non-paired statistics and the DESeq tool.
Panel B shows approach using paired statistics and the edgeR tool. See
text for further details.
doi:10.1371/journal.pone.0034150.g002
Figure 3. Venn diagram shows the number of significant miRs
identified using the non-paired (DESeq) and paired (edgeR)
analysis approach.
doi:10.1371/journal.pone.0034150.g003
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expression of 19 Wnt targets was closely correlated with up-
regulation of KIAA1199, and that the expression in normal mucosa
was limited to cells in the lower portion of colonic crypts [53,54].
The over-expression of KIAA1199 has later been confirmed for
colonic adenomas [55] and gastric cancer [56]. If KIAA1199 and
miR-549 are co-transcribed, this may explain the increased
expression levels of miR-549 found in our study. Furthermore,
as the up-regulation seems to be an early event from previously
published studies, the miR-549 could potentially be a surrogate
biomarker for adenoma development and early adenocarcinoma
stages. This should be further investigated in larger studies.
Table 2. Intersect of significant miRs from the adenocarcinoma cases when using non-paired (DESeq) and paired (edgeR) analysis
approach.
miRNA Log2FC FDR NET Selected relevant cancers with references
Down-regulated
hsa-miR-1 22,0 9,0E-03 No Down-regulated in colorectal [17] and other cancers [32,33].
hsa-miR-139-5p 22,7 5,6E-04 No Down-regulated in gastric [31] and other cancers [32,59].
hsa-miR-145 21,7 2,6E-02 No Down-regulated in colorectal [16,34,36] and other cancers.
hsa-miR-195 22,3 2,2E-03 No Down-regulated in colorectal cancer [39,40].
hsa-miR-363 21,9 2,9E-02 No Down-regulated in colorectal cancer [17].
hsa-miR-378 21,7 3,6E-02 No Down-regulated in colorectal cancer [41].
hsa-miR-378c 21,9 2,3E-02 No Down-regulated in colon cancer [41] and gastric cancer [31].
hsa-miR-383 21,7 7,3E-02 No Down-regulated in gastric cancer [45].
hsa-miR-422a 22,4 2,2E-03 No Down-regulated in colon cancer [60].
hsa-miR-486-5p 22,1 4,7E-02 No Down-regulated in colon and other cancers [61].
hsa-miR-490-3p 21,8 6,5E-02 No Few if any references.
hsa-miR-551b 23,7 4,4E-04 No Down-regulated in colon cancer [17].
hsa-miR-628-3p 26,2 4,1E-04 No Few if any references.
hsa-miR-628-5p 21,7 4,0E-02 No Few if any references.
hsa-miR-1297 26,8 2,9E-02 No Few if any references.
hsa-miR-3151 23,1 1,6E-02 No Few if any references.
hsa-miR-3163 22,1 4,9E-02 No Few if any references.
hsa-miR-3622a-5p 22,0 2,8E-02 No Few if any references.
hsa-miR-3656 22,3 1,9E-02 No Few if any references.
Up-regulated
hsa-miR-7 3,5 6,9E-07 Yes Up- and down-regulated in different cancers (see text).
hsa-miR-96 3,2 1,9E-06 Yes Up-regulated in colon cancer [14,17,50].
hsa-miR-105 4,0 7,5E-02 No Few if any references.
hsa-miR-135b 4,2 2,1E-08 No Up-regulated in colon cancer [14,17,41,50].
hsa-miR-296-3p 1,9 3,5E-02 No Up-regulated in immortalized human cells [52].
hsa-miR-483-3p 3,6 5,1E-05 No Up-regulated in colon, pancreas and other cancers [62,63].
hsa-miR-493 3,4 4,2E-06 No Up-regulated in colon cancer [50].
hsa-miR-549 5,8 8,6E-06 No Few if any references.
hsa-miR-552 4,3 1,7E-07 No Up-regulated in MMR proficient colon cancers and down-regulated in MMR deficient colon
cancers [17].
hsa-miR-584 3,4 1,9E-06 No Up-regulated in colon cancer [17].
hsa-miR-592 3,8 7,0E-06 No Up-regulated in MMR proficient colon cancers and down-regulated in MMR deficient colon
cancers [17].
hsa-miR-1247 1,9 5,3E-02 No Methylated gene (low expression) in HCT116 cells [57]
hsa-miR-1269 4,4 6,3E-07 Yes Few if any references.
hsa-miR-1827 3,0 3,3E-04 Yes Few if any references.
hsa-miR-3144-3p 2,8 4,8E-02 No Few if any references.
hsa-miR-3177 3,2 1,4E-02 Yes Few if any references.
hsa-miR-3180-3p 2,6 4,8E-02 No Few if any references.
hsa-miR-4326 2,5 8,4E-02 No Few if any references.
Adjusted for multiple testing using Benjamini and Hochberg, false discovery rate (FDR) , 0.1. Logarithmic fold change (FC) relative to normal mucosa and FDR from
paired analysis using edgeR. miRs also significant in the analysis of the neuroendocrine tumor (NET) is indicated.
doi:10.1371/journal.pone.0034150.t002
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found that miR-1247 was methylated in HCT116 cells. HCT116
and DLD1 cells were then transfected with a miR-1247 mimic
which resulted in a significant decrease in cell growth and
metabolic activity in both cell lines. DKO cells (HCT 116 cells
deleted for DNA methyltransferase) did however not decrease cell
growth when introduced to the mimic, but caused impaired cell
migration [57]. The role of this miR still remains unclear, but it
has been hypothesized to function as a tumor suppressor. We
found this miR to be up-regulated in the adenocarcinomas, which
could indicate different targets in the pure cell lines compared to
that of an organized tumor tissue.
Finally there are few, if any, reports on the function and role in
colonic adenocarcinomas of the following miRs up-regulated in our
study: -105, -483-3p, -584, -1269, -1827, -3144-3p, -3177, -3180-
3p and -4326 (Table 2).
As we included a neuroendocrine tumor (NET) in this study, we
could take advantage of analyzing this separately using a similar
statistical approach as for the adenocarcinomas. Although, we are
working partially withoutreplicates, the DESeqtool canhandle this
challenge [25]. NETs are rare tumors that originate from
neuroendocrine cells at different sites in the body, including the
gastrointestinal site. There is an increasing incidence, partly due to
better registration and possibly better diagnostic tools [58].
However, very few studies have examined the miR expression in
NET. In our study, the NET shares a few significant miRs with the
adenocarcinomas, but what is more striking are some of the unique
andhighlyexpressedmiRs(TableS2).Thesehavelargefoldchanges
compared to non-paired normal tissues and also a higher relative
expression compared to the adenocarcinomas. The expression
pattern of miRs in the NET differs extensively from the normal
mucosa. This may of course be partly due to the neuroendocrine
tissue itself which is functionally and genetically different from
normal epithelium and stroma. Nevertheless, the identified miRs
may potentially help differentiate between malignant neuroendo-
crinecellsofthecolonandnormalmucosa(asourdatasuggests),and
possibly also between benign neuroendocrine cells and normal
mucosa (no data). The sample size of one means that the NET data
can only be considered indicative. However, in our opinion, the
substantial differences in the sets of differentially regulated miRs
between the two types of cancers deserve to be reported. Our
observation suggests that it may be fruitful to further investigate
thesemiRmarkersastheymaybeusefulinestablishingtheoriginof
poorly differentiated colorectal cancers.
Microdissection of tumor tissue has not been the standard in
studies previously performed. We have however examined the
histopathologyofthetissuespecimens,andestimatedthetumorand
stromal percentages. The tumor percentage was about 67% in
average, well above the average for a subgroup of the KAM cohort
(n=139) which was 49% +/– 24% (data not published). Un-
fortunately,onesampleinthedatasetwasaberrantwithalowtumor
percentage(Table1),andthisisaweaknessofourstudy.Ideally,the
study samples should have had a more homogenous tumor
population. There is however a notion that the normal mucosa
mainly consists of epithelial cells and stroma. When comparing the
tumor tissue and normal mucosa, we are mainly comparing tumor
cells (with varying amounts of stroma) with epithelial cells and
stroma in the normal mucosa. As such, we believe the effect of a too
low tumor percentage will be false negative results.
In high-throughput experiments (whether array or sequencing
based), it is common to perform a validation experiment using
another technology. We performed such a validation experiment
usingaquantitativepolymerasechainreactionforselectedmiRsand
tissue specimens (Figure S1). The results show a positive correlation
between the two different technology platforms. There are seven
miRs for which the fold changes are very different in the validation.
Such differences in fold change between technology platforms are
not unusual as demonstrated by a study of differential miR
expression using the Affymetrix, Agilent, and Illumina microarray
platforms, as well as quantitative PCR and high–throughput
sequencing [28]. Although of concern, this observation does not
invalidate the results obtained. Indeed, it has been observed that
methods for miR gene expression profiling are strongly biased
toward certain miRs, preventing the accurate determination of
absolute numbers. The observed bias is strongly determined by the
method used for library preparation. However, since the biases are
systematic and highly reproducible for a given technology, gene
expression profiling is suited for determining relative expression
differences between samples as long as the same technology is used
acrosssamples[23].Inourstudy,duetothelargeamountsofcDNA
required for the high-throughput sequencing analysis, we did not
have sufficient cDNA available for quantitative PCR validation for
all patients. We therefore had to do a second round of RNA
extraction from adjacent tissue where available. Any heterogeneity
between the adjacent tissues may add to the variability observed in
the validation data (Figure S1).
This study is to our knowledge unique in that global high-
throughput sequencing has been used to characterize miR
expression in paired colorectal cancer tissue and adjacent normal
mucosa. Although preliminary, we believe that the results may
serve as a robust training set for a larger cohort study. We utilized
paired and non-paired statistics, and identified 37 miRs that are
dysregulated in the seven adenocarcinoma cases in both statistical
approaches; 19 down-regulated and 18 up-regulated. Our com-
prehensive survey of differentially expressed miRs confirms some
existing findings. We have also discovered 16 dysregulated miRs
which, to our knowledge, have not previously been associated with
colorectal carcinogenesis. Our results indicate that these may be
important regulators and that further investigations into potential
miR targets and their possible use as predictive or prognostic
markers are warranted. Particularly interesting is the miR-
549 gene located in KIAA1199 which itself has previously been
associated with up-regulation in colonic adenomas and carcino-
mas. If the miR is co-transcribed, it could be a potential surrogate
marker for early disease detection in body fluids or feces. The
study has also shed new light on potential miR biomarkers that
seem to be specific for NETs in the colon.
Materials and Methods
Cohort
Eight colorectal cancer patients were selected from a Norwegian
colorectal cancer cohort (Kolorectalcancer, arv og miljø, KAM) based
on the parameters age and gender. All patients were male with an
average age of 60 years. All of the tissue samples were extracted
from surgical specimens. The normal mucosa was collected in
a distal part of the bowel close to the resection margins. Samples
were subsequently frozen in liquid nitrogen and stored in a freezer
at –80 degrees Celsius. Seven of the patients were confirmed to
have adenocarcinomas and one was characterized as a neuroen-
docrine tumor by histopathological examination. Clinical and
histopathological characteristics of the patients are summarized in
Table 1.
RNA Extraction and Digital Sequencing
Total RNA from the patients was extracted from 10 frozen
sections of 10 mm for tumor and normal tissue respectively using
the mirVana kit (Ambion, TX, USA) according to the manu-
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centrifuge to obtain the necessary concentration of 1 mg/ml. The
presence of small RNA was confirmed on a Bioanalyzer 2100
(Agilent, CA, USA) without sign of degradation when evaluating
OD ratio 260/280. The starting amount was 10 mg of total RNA,
and the preparation protocol was performed according to the
manufacturer’s recommendations. Small RNA was isolated from
total RNA on a 15% Novex TBE-Urea PAGE gel. The area
representing band size of 18–30 nucleotides (nt) was cut out and
fragmented, RNA was eluted in 0.3 M NaCl and purified on
a Spin X column. The 59-adapter was ligated for 6 hours at 20uC.
Small RNA with ligated 59-adapter was isolated on a 15% Novex
TBE-Urea PAGE gel (Invitrogen, CA, USA). The 40–60 nt band
was cut out and fragmented, RNA was eluted in 0.3 M NaCl and
purified on a Spin X column. The 39-adapter was ligated for 6
hours at 20uC. Small RNAs with ligated 59- and 39-adapters were
isolated on a 10% Novex TBE-Urea PAGE gel, the 70–90 nt band
was cut out and fragmented, RNA was eluted in 0.3 M NaCl and
cleaned on a Spin X column. Then GlycoBlue and ethanol were
added followed by precipitation for 30 minutes at –80uC and
centrifugation at 14 000 rpm for 25 minutes. The RNA pellet was
dissolved in 4.5 ml RNase free water. Reverse transcription and
amplification was carried out and the cDNA was separated on
a 6% Novex TBE PAGE gel. The amplified cDNA band was cut
out and fragmented; RNA was eluted in Gel Elution Buffer and
purified on a Spin X column. Then glycogen and ethanol were
added for precipitation followed by centrifugation at 14 000 rpm
and 4uC for 20 minutes. The cDNA pellet was dissolved in 10 ml
Resuspension Buffer. The cDNA library generated was evaluated
with a quantitative real-time PCR to ensure acceptable quality and
confirm that adapters were correctly added. The high-throughput
sequencing of the cDNA was done in a 36 bp single read run on
an Illumina Genome Analyzer IIx (Illumina, CA, USA). Image
analysis and base calling was performed with the Illumina GA
pipeline software version 1.5.1. Sequences with a chastity less than
0.6 on two or more bases among the first 25 bases were filtered out
(this is the default setting for the software).
Experimental Validation with RT Real-time PCR
A total of six miRs (miR-1, -21, -143, -145, -423-5p and -192)
were selected for experimental validation using a reverse tran-
scription (RT) real-time PCR protocol. Total RNA from three
patients (six tissue specimens) was re-extracted as previously
described due to shortage of total RNA from first extraction batch.
cDNA was constructed from total RNA using the TaqMan
MicroRNA Reverse Transcription Kit and Megaplex RT Primers
Pool A (Applied Biosystems). Pre-amplification of cDNA was
performed using Megaplex PreAmp Primers (Applied Biosystems)
to increase the starting amount prior to gene expression analysis. It
enables an unbiased pre-amplification prior to loading the
TaqMan MicroRNA Array according to the manufacturer’s
instructions. Single sequence-specific miR real-time PCR assays
were used to quantitate each individual mature miRNA (Applied
Biosystems, Assay IDs; 002222, 000397, 002249, 002278, 002340
and 000491) using a TaqMan MGB probe. Expression of RNU44
and RNU48 were tested across a set of miR samples (n=20) from
colorectal cancer patients, and they were both found to have stable
expression across samples. RNU48 was used as endogenous
control. The DDCt method was used for calculating the relative
expression of a given miR between a paired normal and tumor
sample. Fold change was further calculated as 2
-DDC. For the
digital gene expression data, the count data was normalized to the
estimated size factors (DESeq). Fold change was calculated as the
ratio between normalized count data for tumor and normal
samples. Fold changes for the high-throughput sequencing and
quantitative PCR were log transformed and plotted with an
expected trend line (Figure S1).
Data Analysis
Data from the high throughput sequencing was obtained in
FASTQ format, one data file per sequencing lane (n=16). The
sequencing adaptors were subsequently clipped and removed
using the FASTX-Toolkit (http://hannonlab.cshl.edu/
fastx_toolkit/), allowing no mismatches for adaptor identification.
The remaining sequencing data was further collapsed and
counted into groups of identical sequences. The sequencing data
was further processed using the miRanalyzer tool version 0.2 [24].
This tool allows for the identification of validated miRs from the
miRBase (release 16) data repository [8] and includes a machine
learning algorithm for the prediction of novel miRs. It also
evaluates sequence alignment to other entities through the
databases RefSeq and Rfam. Sequence data was aligned to the
Homo Sapiens hg18 genome reference allowing for one mis-
match.
Differential expression (DE) of identified miRs from miRBase
was calculated with R version 2.13.0 using DESeq version 1.4.1
[25] and edgeR version 2.2.5 [26] available in Bioconductor
version 2.8. Both tools utilize a negative binomial distribution for
modeling read counts per miR and implement a method for
normalizing the counts. We began by ignoring the pairing
information between the samples: differential expression (fold
change) of known miRs was analyzed between the group of
adenocarcinoma (n=7) and normal mucosa (n=8), subsequently
between the neuroendocrine case (n=1) and normal mucosa
(n=8) using DESeq. A diagnostic plot provided in the supple-
mentary materials for the fit of the variance function (Figure S2)
shows how the use of the negative binomial model enables a good
estimation of the variance (something that would not have been
possible with a Poisson model). P-values are adjusted for multiple
testing using the Benjamini and Hochberg method [27]. Only
miRs with a fold change with adjusted P-value with false discovery
rate (FDR) , 0.1 are considered significant [25]. Since all samples
of cancerous and normal mucosal tissues are paired from the same
patients, we also performed a test of all adenocarcinoma cases
using paired statistics in edgeR with a generalized linear model
(GLM) method. This method was adjusted for multiple testing as
above. The miR count data for all samples (Dataset S1) and the R
code (Text S1) are available online.
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